DNTH Stock Forecast & Price Target

Dianthus Therapeutics is a single segment biotech company focused on developing treatments for severe autoimmune diseases with an experienced team and a promising pipeline, including classeprubart for MMN with results expected in 2026 and DNTH312, a differentiated bifunctional fusion protein with comparable potency and longer half-life in preclinical studies. With updated financials and a new $158 per share target, Wedbush has an Outperform rating on Dianthus, pointing to their "flags in the ground" with earlier clinical development, potential for accelerated approval, and a broader market opportunity with DNTH212 in Sjogren's disease, SLE, and DM.

Dianthus Therapeutics is expected to remain an outperform stock, with a new target of $105. The company's performance in the first quarter of 2026 showed promising updates, particularly in the narrowing of timing for the Claseprubart Phase 2 MMN study and the disclosure of development indications for DNTH212. We are waiting for further clarity on proof-of-concept studies and healthy volunteer data before determining credit, but the potential for positive results is there, especially with the company's prioritization of development in Sjogren's disease, SLE, and DM. Additionally, Classenprubart's demonstrated potency may lead to meaningful improvements in the time to IVIg re-treatment, further supporting our positive outlook.